MiMedx Group (NASDAQ:MDXG) Releases Earnings Results

MiMedx Group (NASDAQ:MDXG) announced its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05), FiscalAI reports. The company had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a return on equity of 11.72% and a net margin of 1.76%.

Here are the key takeaways from MiMedx Group’s conference call:

• Sanara MedTech acquisition: MiMedx agreed to acquire Sanara for $35 per share, creating a combined regenerative medicine company expected to generate more than $400 million in 2027 revenue, double-digit growth, over 20% adjusted EBITDA margins, and at least $20 million in annual cost synergies.
• Surgical momentum remained strong: Second-quarter surgical revenue increased 15% year over year, with broad-based growth across the portfolio, while the Sanara deal is expected to expand MiMedx’s surgical addressable market by approximately $4 billion.
• Wound care showed early stabilization: Wound revenue rose 11% sequentially and volume increased 22%, including 44% sequential growth in wound care centers, but revenue remained down 61% year over year because of substantially reduced Medicare reimbursement and ongoing administrative challenges.
• Second-quarter profitability deteriorated: Net sales fell 35% year over year to $64 million, adjusted EBITDA was negative $8 million, and gross margin declined to 69%; results included an additional $5 million bad-debt charge tied mainly to private-office accounts.
• Financing and outlook: MiMedx reiterated 2026 standalone revenue guidance of $260 million to $290 million and expects adjusted EBITDA to approach breakeven, while financing the Sanara acquisition with a $300 million term loan carrying interest at SOFR plus 6.25%.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG traded down $0.18 during trading on Friday, reaching $4.08. The stock had a trading volume of 1,478,079 shares, compared to its average volume of 1,313,592. The stock has a market capitalization of $608.44 million, a PE ratio of 102.15 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.39 and a quick ratio of 4.81. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.99. The business’s 50-day moving average price is $3.91 and its 200 day moving average price is $4.24.

Analyst Upgrades and Downgrades

Several research analysts recently commented on MDXG shares. Wall Street Zen cut MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings cut shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Citizens Jmp reduced their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Finally, Craig Hallum decreased their target price on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDXG. Nantahala Capital Management LLC acquired a new position in shares of MiMedx Group during the third quarter worth approximately $10,237,000. Marshall Wace LLP raised its position in MiMedx Group by 864.9% in the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock worth $9,351,000 after purchasing an additional 1,238,132 shares during the last quarter. Disciplined Growth Investors Inc. MN raised its position in MiMedx Group by 283.0% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock worth $9,656,000 after purchasing an additional 1,022,202 shares during the last quarter. Millennium Management LLC lifted its holdings in MiMedx Group by 93.9% during the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after buying an additional 596,016 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in MiMedx Group by 5,332.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 559,058 shares of the company’s stock worth $3,416,000 after buying an additional 548,767 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.